RECENTLY REGSITERED COMPANIES:
What to Expect at the Only Industry-Focused Summit
Dedicated to Covalent Drug Development’
As more covalent candidates enter the clinic and more companies turn to covalency to overcome efficacy and safety challenges, confidence in covalency is growing. Amongst this buzz, the 3rd Covalent Drug Discovery & Development Summit returns to Boston with a completely refreshed speaker faculty to deliver the most up-to-date insights on everything covalent.
Covering end-to-end challenges, from covalent library generation and hit identification, to modelling PK/PD and exploring novel covalent modalities, this meeting is dedicated to equipping covalent experts like yourself with the tools, lessons and data to discover the next wave of clinically successful covalent therapies.
Why Should You Attend?
Expand the druggable proteome and target previously ‘undruggable’ proteins including transcription factors and splicing machinery to unlock treatment options for diseases with unmet medical need. Featuring data from Talus Bio and BridGene Biosciences.
Achieve balanced selectivity and reactivity of covalent warheads through strategic lead optimization and drug design to ensure the development of tolerable, durable and potent therapies. Strategies from Flare Therapeutics and AstraZeneca
Discover the unique therapeutic potential of covalency across a diverse range of modalities, including covalent activators and radiopharmaceuticals, with case studies from Actithera and Dana Farber Cancer Institute.
Strategize clinical development protocols with confidence by accurately elucidating PK/PD relationships, characterizing ADME and measuring target engagement to inform dosing. Insight from Novartis and Frontier Medicines
Unleash the next wave of best-in-class covalent therapies with advanced screening technologies, covalent libraries, chemoproteomics platforms and computational modelling. With learnings from UC Berkeley and Vividion Therapeutics
Key Sessions Not To Miss
Reimagining Druggability using Chemoproteomic Platforms
Daniel Nomura, Professor, University of California at Berkeley
Structural Biology & Computational Challenges in Covalent Targeting of Cryptic Pockets
Brendan Hilbert, Director, Protein & Structural Biology, Antares Therapeutics
Discovery of Bispecific T-Cell Engagers Targeting Covalent Drug-Modified KRASG12C Neoantigens
Sean Toenjes, Executive Director, Chemistry & Innovation, Aethon Therapeutics
Complementary Strategies for Covalent Hit Finding & Characterization
Markus Schirle, Executive Director, Novartis
Discovery of RMC-9805, an Oral, RAS(ON)G12D-Selective Covalent Tri-Complex Inhibitor
Sujata Chakraborty, Senior Scientist, Revolution Medicines
Explore the Full Event Guide
-
-
- 19+ expert speakers
- 7+ hours of dedicated networking
- 3 days of data-driven, covalent specific content
- 2 interactive, deep-dive workshops
-
